End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.35 CNY | +1.68% | -3.14% | -8.91% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company sustains low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 48.09 times its estimated earnings per share for the ongoing year.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.91% | 1.24B | - | ||
-8.74% | 60.39B | A- | ||
+61.90% | 45.4B | B | ||
+14.54% | 38.12B | B | ||
+1.03% | 31.28B | A- | ||
+9.32% | 19.67B | B- | ||
+10.83% | 16.52B | C+ | ||
+7.90% | 13.8B | B- | ||
-5.22% | 12.96B | B | ||
-23.61% | 12.42B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 600955 Stock
- Ratings Lihuayi Weiyuan Chemical Co., Ltd.